Yoshida, K.; Enomoto, M.; Tamori, A.; Nishiguchi, S.; Kawada, N.
Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. Int. J. Mol. Sci. 2021, 22, 1456.
https://doi.org/10.3390/ijms22031456
AMA Style
Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N.
Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. International Journal of Molecular Sciences. 2021; 22(3):1456.
https://doi.org/10.3390/ijms22031456
Chicago/Turabian Style
Yoshida, Kanako, Masaru Enomoto, Akihiro Tamori, Shuhei Nishiguchi, and Norifumi Kawada.
2021. "Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy" International Journal of Molecular Sciences 22, no. 3: 1456.
https://doi.org/10.3390/ijms22031456
APA Style
Yoshida, K., Enomoto, M., Tamori, A., Nishiguchi, S., & Kawada, N.
(2021). Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. International Journal of Molecular Sciences, 22(3), 1456.
https://doi.org/10.3390/ijms22031456
